Jiangbo Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiangbo Lin has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Fei-Long Guo
Department of Thoracic Surgery, Fujian Medical University Union Hospital
9 shared publicationsJiang-Shan Huang
Department of Thoracic Surgery, Fujian Medical University Union Hospital
8 shared publicationsMingqiang Kang
Fujian Medical University Union Hospital
8 shared publicationsQi-Hong Zhong
Department of Thoracic Surgery, Fujian Medical University Union Hospital
8 shared publicationsJing-Yu Wu
Department of Thoracic Surgery, Fujian Medical University Union Hospital
7 shared publicationsSui Chen
Department of Thoracic Surgery, Fujian Medical University Union Hospital
7 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1994701
Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
Introduction: This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. Methods: All patients received neoadjuvant therapy followed by minimally invasive McKeown esophagectomy and were categorized according to treatment modality: neoadjuvant chemotherapy (nCT), chemoradiotherapy (nCRT), or chemoimmunotherapy (nICT). Propensity score matching yielded 78 patients per group. The primary endpoints were 3-year overall survival (OS), recurrence-free survival (RFS), and recurrence patterns. Results: One-year RFS was significantly lower in the nCT group than in the nCRT and nICT groups ( p = 0.020), whereas 2-year OS was significantly higher in the nICT group ( p = 0.018). However, no statistically significant differences were observed in 3-year OS or RFS. Recurrence occurred significantly earlier in the nCT group than in the nICT group ( p < 0.05), with no statistically significant differences in the other pairwise comparisons. Discussion: In this retrospective matched-cohort study, nICT did not significantly improve 3-year OS or RFS compared with nCRT, although recurrence appeared to occur later in the nICT group. These findings should be interpreted as hypothesis-generating, as potential long-term immunotherapy effects and radiotherapy-related modulation of long-term benefit could not be assessed. The lower survival observed in the nCT group suggests that chemotherapy alone may be insufficient for ESCC. Prospective trials are warranted to confirm long-term benefits and identify patients most likely to benefit from nICT.
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1994701
Open AccessEfficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
Introduction: This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. Methods: All patients received neoadjuvant therapy followed by minimally invasive McKeown esophagectomy and were categorized according to treatment modality: neoadjuvant chemotherapy (nCT), chemoradiotherapy (nCRT), or chemoimmunotherapy (nICT). Propensity score matching yielded 78 patients per group. The primary endpoints were 3-year overall survival (OS), recurrence-free survival (RFS), and recurrence patterns. Results: One-year RFS was significantly lower in the nCT group than in the nCRT and nICT groups ( p = 0.020), whereas 2-year OS was significantly higher in the nICT group ( p = 0.018). However, no statistically significant differences were observed in 3-year OS or RFS. Recurrence occurred significantly earlier in the nCT group than in the nICT group ( p < 0.05), with no statistically significant differences in the other pairwise comparisons. Discussion: In this retrospective matched-cohort study, nICT did not significantly improve 3-year OS or RFS compared with nCRT, although recurrence appeared to occur later in the nICT group. These findings should be interpreted as hypothesis-generating, as potential long-term immunotherapy effects and radiotherapy-related modulation of long-term benefit could not be assessed. The lower survival observed in the nCT group suggests that chemotherapy alone may be insufficient for ESCC. Prospective trials are warranted to confirm long-term benefits and identify patients most likely to benefit from nICT.
- Open Access
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1805033
A novel short-term outcome prediction model for esophagectomy patients receiving neoadjuvant immunochemotherapy and neoadjuvant chemotherapy: a muti-center retrospective study
Background: Due to the lack of a comprehensive evaluation of the short-term prognosis of patients undergoing radical resection of esophageal cancer after neoadjuvant therapy, recent clinical strategies have remained subjective and controversial. The recognition of pretreatment risk factors and tailored treatment could improve outcomes of esophagectomy patients. Therefore, we aimed to develop a predictive model that differentiates high-risk conditions after surgery in patients with esophageal cancer receiving neoadjuvant therapy. Methods: We conducted a muti-center, retrospective cohort study in Fujian Medical University Union Hospital, Ganzhou Cancer Hospital and Affiliated Hospital of Jinggangshan University. A principal component (PC) analysis was applied for data simplification and the extraction of patient short-term outcome characteristic. We identified risk status on admission and operation, via a logistic regression and then constructed prediction models for worsened short-term outcomes. Results: Of 334 patients of train set underwent neoadjuvant therapy and esophagectomy, 142(42.5%) received neoadjuvant chemotherapy (NC), 192(57.5%) received neoadjuvant immunochemotherapy (NIC). After grouping by principal component analysis, patients were divided into high-risk group (83,25%) and low-risk group (251,75%). Twelve features regarding clinical feature, nutrition indicators, laboratory indicators and intraoperative data were identified. The prediction model showed the best performance in predicting high short-term outcome risk, with an area under the receiver operating characteristic curve (AUC) of 0.794 (95%CI, 0.712,0.876) in NC, and 0.781 (95%CI, 0.705,0.858) in NIC. Conclusion: A novel short-term outcome prediction model, offers a comprehensive assessment of posttreatment recovery in esophagectomy patients after neoadjuvant immunotherapy combined with chemotherapy and neoadjuvant chemotherapy.
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1805033
Open AccessA novel short-term outcome prediction model for esophagectomy patients receiving neoadjuvant immunochemotherapy and neoadjuvant chemotherapy: a muti-center retrospective study
Background: Due to the lack of a comprehensive evaluation of the short-term prognosis of patients undergoing radical resection of esophageal cancer after neoadjuvant therapy, recent clinical strategies have remained subjective and controversial. The recognition of pretreatment risk factors and tailored treatment could improve outcomes of esophagectomy patients. Therefore, we aimed to develop a predictive model that differentiates high-risk conditions after surgery in patients with esophageal cancer receiving neoadjuvant therapy. Methods: We conducted a muti-center, retrospective cohort study in Fujian Medical University Union Hospital, Ganzhou Cancer Hospital and Affiliated Hospital of Jinggangshan University. A principal component (PC) analysis was applied for data simplification and the extraction of patient short-term outcome characteristic. We identified risk status on admission and operation, via a logistic regression and then constructed prediction models for worsened short-term outcomes. Results: Of 334 patients of train set underwent neoadjuvant therapy and esophagectomy, 142(42.5%) received neoadjuvant chemotherapy (NC), 192(57.5%) received neoadjuvant immunochemotherapy (NIC). After grouping by principal component analysis, patients were divided into high-risk group (83,25%) and low-risk group (251,75%). Twelve features regarding clinical feature, nutrition indicators, laboratory indicators and intraoperative data were identified. The prediction model showed the best performance in predicting high short-term outcome risk, with an area under the receiver operating characteristic curve (AUC) of 0.794 (95%CI, 0.712,0.876) in NC, and 0.781 (95%CI, 0.705,0.858) in NIC. Conclusion: A novel short-term outcome prediction model, offers a comprehensive assessment of posttreatment recovery in esophagectomy patients after neoadjuvant immunotherapy combined with chemotherapy and neoadjuvant chemotherapy.
- Open Access
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790677
Bovine pericardial patch for preventing air leak after thoracoscopic-assisted pulmonary wedge resection: a retrospective cohort study with predictive modeling
Background: Thoracoscopic wedge resection has become a standard procedure for pulmonary nodule management, yet postoperative air leak (PAL) remains a prevalent complication. While bovine pericardial patches are established in cardiovascular surgery, their utility in pulmonary resection merits further investigation. This study aimed to assess the efficacy of bovine pericardial patches in reducing PAL after thoracoscopic wedge resection and develop a predictive model for clinical utility. Methods: In this single-center retrospective study (2015-2020), we analyzed 2006 thoracoscopic wedge resections at Fujian Medical University Union Hospital, comparing 319 patch-treated cases with 1,687 controls. Primary outcomes included PAL incidence; while secondary outcomes encompassed drainage duration. Univariate and multivariate logistic regression analyses identified risk factors for PAL, and a nomogram was constructed to predict PAL risk. Results: Baseline characteristics were well-balanced between groups. The bovine pericardial patch group showed a significantly lower PAL incidence (2.8% vs. 13.2%, P < 0.001) and shorter chest tube drainage duration (2.85 ± 1.27 days vs. 3.06 ± 1.67 days, P = 0.033). Multivariate analysis confirmed the bovine pericardium patch as an independent protective factor against PAL (OR: 0.170; 95% CI: 0.079-0.322; P < 0.001). The nomogram incorporating these factors showed good discriminative ability (AUC = 0.739) and clinical utility in decision curve analysis. Conclusion: Bovine pericardial patch application significantly reduces PAL incidence and shortens chest tube drainage duration after thoracoscopic wedge resection. The predictive nomogram helps identify high-risk patients who would benefit most from this intervention, supporting its use as a cost-effective adjunct in pulmonary surgery.
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1790677
Open AccessBovine pericardial patch for preventing air leak after thoracoscopic-assisted pulmonary wedge resection: a retrospective cohort study with predictive modeling
Background: Thoracoscopic wedge resection has become a standard procedure for pulmonary nodule management, yet postoperative air leak (PAL) remains a prevalent complication. While bovine pericardial patches are established in cardiovascular surgery, their utility in pulmonary resection merits further investigation. This study aimed to assess the efficacy of bovine pericardial patches in reducing PAL after thoracoscopic wedge resection and develop a predictive model for clinical utility. Methods: In this single-center retrospective study (2015-2020), we analyzed 2006 thoracoscopic wedge resections at Fujian Medical University Union Hospital, comparing 319 patch-treated cases with 1,687 controls. Primary outcomes included PAL incidence; while secondary outcomes encompassed drainage duration. Univariate and multivariate logistic regression analyses identified risk factors for PAL, and a nomogram was constructed to predict PAL risk. Results: Baseline characteristics were well-balanced between groups. The bovine pericardial patch group showed a significantly lower PAL incidence (2.8% vs. 13.2%, P < 0.001) and shorter chest tube drainage duration (2.85 ± 1.27 days vs. 3.06 ± 1.67 days, P = 0.033). Multivariate analysis confirmed the bovine pericardium patch as an independent protective factor against PAL (OR: 0.170; 95% CI: 0.079-0.322; P < 0.001). The nomogram incorporating these factors showed good discriminative ability (AUC = 0.739) and clinical utility in decision curve analysis. Conclusion: Bovine pericardial patch application significantly reduces PAL incidence and shortens chest tube drainage duration after thoracoscopic wedge resection. The predictive nomogram helps identify high-risk patients who would benefit most from this intervention, supporting its use as a cost-effective adjunct in pulmonary surgery.
- 6 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2222-2223
ASO Visual Abstract: Tumor-Intrinsic Microbiome-Based Subtyping of Esophageal Cancer as Predictive Biomarkers for Postoperative Survival
- 6 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2222-2223
ASO Visual Abstract: Tumor-Intrinsic Microbiome-Based Subtyping of Esophageal Cancer as Predictive Biomarkers for Postoperative Survival
- Open Access
- 8 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1682377
Comparison of short-term outcomes of combined neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy, and neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
Background: This study aimed to evaluate the safety and efficacy of neoadjuvant immunochemotherapy (nICT) compared to those of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods: Patients with locally advanced resectable ESCC undergoing neoadjuvant therapy followed by minimally invasive McKeown esophagectomy (MIE) between January 1, 2019, and January 1, 2022, were categorized into the nCT, nCRT, and nICT groups. Inverse probability of treatment weighting (IPTW) was used to balance the 13 baseline covariates across the groups. Post-IPTW comparisons included adverse events, surgical outcomes, pathologic complete response (PCR), tumor downstaging, and perioperative complications. Results: A total of 437 patients were enrolled (nICT = 218, nCRT = 78, nCT = 141). After propensity score matching (PSM), 78 patients were included in each group. During neoadjuvant therapy, the incidence of leukopenia was significantly higher in the nCRT (33.33%) and nICT (23.08%) groups than in the nCT (10.26%), p < 0.05. Neutropenia rates followed a similar trend (nCRT: 19.23%; nICT: 17.95%; nCT: 2.56%, p < 0.05). Immune-related dermatitis occurred in 10.26% of patients with nICT. Operative duration was significantly longer with nCRT (347.8 ± 80.8 min) than nCT (325.1 ± 52.6 min; p < 0.05). The tumor-downstaging efficacy was ranked as follows: nICT > nCRT > nCT ( p < 0.05). Lymph node dissection:Yields: nCRT (26 ± 11) < nICT (36 ± 14) and nCT (35 ± 12) ( p < 0.05),Stations: nICT (13 ± 4) > nCRT (9 ± 2) and nCT (11 ± 2) ( p < 0.05). The PCR rates were 34.61% (nCRT), 26.92% (nICT), and 5.13% (nCT), respectively ( p < 0.05). Postoperative 30-day mortality occurred in three nCRT and one nCT patients. Postoperative arrhythmia incidence was highest with nICT (12.82%), intermediate with nCT (5.13%), and absent with nCRT (0.00%). Conclusion: For locally advanced resectable ESCC, nCRT requires vigilant management because of its association with grade 3 treatment-related adverse events (AEs). While nICT demonstrates a lower incidence of severe (grade ≥ 3) non-immune toxicities compared to nCRT, supporting its controllable safety. nCRT achieved superior PCR rates versus nICT/nCT, but nICT showed greater nodal (N) downstaging efficacy. Conversely, nCRT provided enhanced primary tumor (T) control.
- 8 December 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1682377
Open AccessComparison of short-term outcomes of combined neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy, and neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
Background: This study aimed to evaluate the safety and efficacy of neoadjuvant immunochemotherapy (nICT) compared to those of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods: Patients with locally advanced resectable ESCC undergoing neoadjuvant therapy followed by minimally invasive McKeown esophagectomy (MIE) between January 1, 2019, and January 1, 2022, were categorized into the nCT, nCRT, and nICT groups. Inverse probability of treatment weighting (IPTW) was used to balance the 13 baseline covariates across the groups. Post-IPTW comparisons included adverse events, surgical outcomes, pathologic complete response (PCR), tumor downstaging, and perioperative complications. Results: A total of 437 patients were enrolled (nICT = 218, nCRT = 78, nCT = 141). After propensity score matching (PSM), 78 patients were included in each group. During neoadjuvant therapy, the incidence of leukopenia was significantly higher in the nCRT (33.33%) and nICT (23.08%) groups than in the nCT (10.26%), p < 0.05. Neutropenia rates followed a similar trend (nCRT: 19.23%; nICT: 17.95%; nCT: 2.56%, p < 0.05). Immune-related dermatitis occurred in 10.26% of patients with nICT. Operative duration was significantly longer with nCRT (347.8 ± 80.8 min) than nCT (325.1 ± 52.6 min; p < 0.05). The tumor-downstaging efficacy was ranked as follows: nICT > nCRT > nCT ( p < 0.05). Lymph node dissection:Yields: nCRT (26 ± 11) < nICT (36 ± 14) and nCT (35 ± 12) ( p < 0.05),Stations: nICT (13 ± 4) > nCRT (9 ± 2) and nCT (11 ± 2) ( p < 0.05). The PCR rates were 34.61% (nCRT), 26.92% (nICT), and 5.13% (nCT), respectively ( p < 0.05). Postoperative 30-day mortality occurred in three nCRT and one nCT patients. Postoperative arrhythmia incidence was highest with nICT (12.82%), intermediate with nCT (5.13%), and absent with nCRT (0.00%). Conclusion: For locally advanced resectable ESCC, nCRT requires vigilant management because of its association with grade 3 treatment-related adverse events (AEs). While nICT demonstrates a lower incidence of severe (grade ≥ 3) non-immune toxicities compared to nCRT, supporting its controllable safety. nCRT achieved superior PCR rates versus nICT/nCT, but nICT showed greater nodal (N) downstaging efficacy. Conversely, nCRT provided enhanced primary tumor (T) control.
- 20 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2189-2201
Tumor-Intrinsic Microbiome-Based Subtyping of Esophageal Cancer as Predictive Biomarkers for Postoperative Survival
This study aims to investigate the impact of different treatment regimens on the intratumoral microbiota (ITM) composition in esophageal cancer patients an
- 20 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (3) , 2189-2201
Tumor-Intrinsic Microbiome-Based Subtyping of Esophageal Cancer as Predictive Biomarkers for Postoperative Survival
This study aims to investigate the impact of different treatment regimens on the intratumoral microbiota (ITM) composition in esophageal cancer patients an
- 9 October 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 332 (Pt 2) , 148121
Comprehensive multi-omics analysis identifies transferrin receptor as a therapeutic target in esophageal cancer
- 9 October 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 332 (Pt 2) , 148121
Comprehensive multi-omics analysis identifies transferrin receptor as a therapeutic target in esophageal cancer
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 163-177
Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy
Objective: To evaluate the efficacy of combined tumor immunoscore (IS) and pan-immune inflammation value (PIV) in assessing pathological response and survival following neoadjuvant chemoimmunotherapy (NACI) in locally advanced esophageal squamous cell carcinoma (ESCC). Methods: A retrospective cohort of 226 ESCC patients undergoing NACI followed by surgery was analyzed. Local immune status was assessed via IS calculated from CD3⁺/CD8⁺ T-cell densities on immunohistochemical stained tumor sections. Systemic inflammation was measured by peripheral blood PIV. Patients were stratified by median values. The association of IS, PIV alone, and their combination for major pathological response (TRG 0–1) and overall survival (OS) was evaluated. Results: The pathological response rate was significantly higher in the high IS group versus the low IS group (54.3% vs. 38.6%; P = 0.023) and in the low PIV group p versus the high PIV group (67.3% vs. 21.2%; P < 0.001). In the combined model, the low IS + high PIV group (Group D) exhibited the lowest pathological response rate (32.0%) and a significantly increased risk of death compared with the optimal group [high IS + low PIV; Group A; hazard ratios = 2.85; 95% confidence interval (CI): 1.70–4.77; P < 0.001]. The dual-parameter IS + PIV model demonstrated superior discriminatory performance: area under the curve (AUC) = 0.78 (95% CI: 0.73–0.84) for discriminating pathological response and AUC = 0.82 (95% CI: 0.75–0.88) for predicting 36-month OS, significantly outperforming single parameters and clinical staging. Conclusion: The IS + PIV dual-parameter model, by integrating local immune activity and systemic inflammatory status, accurately identifies NACI beneficiaries (high IS + low PIV) and high-risk patients (low IS + high PIV), providing an efficient prognostic tool for personalized treatment strategies.
- 7 October 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 163-177
Open AccessCombined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy
Objective: To evaluate the efficacy of combined tumor immunoscore (IS) and pan-immune inflammation value (PIV) in assessing pathological response and survival following neoadjuvant chemoimmunotherapy (NACI) in locally advanced esophageal squamous cell carcinoma (ESCC). Methods: A retrospective cohort of 226 ESCC patients undergoing NACI followed by surgery was analyzed. Local immune status was assessed via IS calculated from CD3⁺/CD8⁺ T-cell densities on immunohistochemical stained tumor sections. Systemic inflammation was measured by peripheral blood PIV. Patients were stratified by median values. The association of IS, PIV alone, and their combination for major pathological response (TRG 0–1) and overall survival (OS) was evaluated. Results: The pathological response rate was significantly higher in the high IS group versus the low IS group (54.3% vs. 38.6%; P = 0.023) and in the low PIV group p versus the high PIV group (67.3% vs. 21.2%; P < 0.001). In the combined model, the low IS + high PIV group (Group D) exhibited the lowest pathological response rate (32.0%) and a significantly increased risk of death compared with the optimal group [high IS + low PIV; Group A; hazard ratios = 2.85; 95% confidence interval (CI): 1.70–4.77; P < 0.001]. The dual-parameter IS + PIV model demonstrated superior discriminatory performance: area under the curve (AUC) = 0.78 (95% CI: 0.73–0.84) for discriminating pathological response and AUC = 0.82 (95% CI: 0.75–0.88) for predicting 36-month OS, significantly outperforming single parameters and clinical staging. Conclusion: The IS + PIV dual-parameter model, by integrating local immune activity and systemic inflammatory status, accurately identifies NACI beneficiaries (high IS + low PIV) and high-risk patients (low IS + high PIV), providing an efficient prognostic tool for personalized treatment strategies.
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Pan-immune-inflammation value as a novel predictor of pathological response to neoadjuvant chemotherapy combined with anti-PD-1 therapy in esophageal squamous cell carcinoma: a multicenter real-world retrospective clinical study
Background: Current biomarkers for predicting pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma (ESCC) remain limited. Objective: This study investigates the potential of the pan-immune-inflammation value (PIV) as a biomarker for predicting pathological response after neoadjuvant chemoradiotherapy combined with anti-programmed death protein-1 (PD-1) therapy in ESCC. Design: A multicenter, real-world, retrospective clinical study conducted across five centers in Southern China (January 2021–March 2024). Methods: A multicenter retrospective study included 334 patients with ESCC, divided into pathological complete response (pCR) and non-pathological complete response (non-pCR) groups. Clinical and laboratory data were analyzed using univariate and multivariate logistic regression to evaluate the relationship between post-treatment PIV and pathological response. The threshold effect of PIV was explored using restricted cubic spline analysis. Results: Subgroup analysis showed no significant interactions across clinical subgroups. Post-treatment PIV was positively associated with non-pCR risk (odds ratio = 1.002; 95% confidence interval: 1.001–1.003, p < 0.005). A positive association was observed in the high-PIV stratum (⩾280), where elevated PIV levels significantly correlated with increased non-pCR risk. Receiver operating characteristic analysis showed an area under the curve of 0.86 for predicting non-pCR, with a sensitivity of 86.6% and specificity of 72% at an optimal cutoff of 438.04. The high-PIV group exhibited inferior survival outcomes with significantly increased mortality risk. Conclusion: Post-treatment PIV shows a nonlinear relationship with pathological response in patients receiving neoadjuvant chemoradiotherapy combined with anti-PD-1 therapy and may serve as a predictive biomarker.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessPan-immune-inflammation value as a novel predictor of pathological response to neoadjuvant chemotherapy combined with anti-PD-1 therapy in esophageal squamous cell carcinoma: a multicenter real-world retrospective clinical study
Background: Current biomarkers for predicting pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma (ESCC) remain limited. Objective: This study investigates the potential of the pan-immune-inflammation value (PIV) as a biomarker for predicting pathological response after neoadjuvant chemoradiotherapy combined with anti-programmed death protein-1 (PD-1) therapy in ESCC. Design: A multicenter, real-world, retrospective clinical study conducted across five centers in Southern China (January 2021–March 2024). Methods: A multicenter retrospective study included 334 patients with ESCC, divided into pathological complete response (pCR) and non-pathological complete response (non-pCR) groups. Clinical and laboratory data were analyzed using univariate and multivariate logistic regression to evaluate the relationship between post-treatment PIV and pathological response. The threshold effect of PIV was explored using restricted cubic spline analysis. Results: Subgroup analysis showed no significant interactions across clinical subgroups. Post-treatment PIV was positively associated with non-pCR risk (odds ratio = 1.002; 95% confidence interval: 1.001–1.003, p < 0.005). A positive association was observed in the high-PIV stratum (⩾280), where elevated PIV levels significantly correlated with increased non-pCR risk. Receiver operating characteristic analysis showed an area under the curve of 0.86 for predicting non-pCR, with a sensitivity of 86.6% and specificity of 72% at an optimal cutoff of 438.04. The high-PIV group exhibited inferior survival outcomes with significantly increased mortality risk. Conclusion: Post-treatment PIV shows a nonlinear relationship with pathological response in patients receiving neoadjuvant chemoradiotherapy combined with anti-PD-1 therapy and may serve as a predictive biomarker.
- Open Access
- 25 March 2025
- Published by Springer Nature in Perioperative Medicine
- Vol. 14 (1) , 1-12
Prediction of esophagogastric anastomotic leakage by nomogram combined with preoperative nutritional status and clinical factors: a retrospective study of 775 patients
The purpose was to explore the independent risk factors for esophagogastric anastomotic leakage (EGAL) and establish a nomogram. Patients who underwent esophagectomy were enrolled and randomly divided into a training cohort and a validation cohort at a ratio of 7:3. The differences between the two groups of factors were analyzed by difference analysis, and multivariate regression analysis was subsequently performed. A nomogram was established, and the feasibility of the nomogram was verified by analyzing the discrimination, calibration, and decision curves. A total of 775 patients were enrolled, including 532 in the training cohort and 223 in the validation cohort. Multivariate regression analysis revealed that age, smoking history, drinking history, nutritional indicators, and anastomotic location were independent risk factors. In terms of discrimination, in the training group, the area under the curve was 0.757 (P = 0.025). In the calibration curve, the curves and fitting lines before and after correction in the training group and the validation group were basically the same. The results of the Hosmer–Lemeshow test showed that the chi-square value of the training cohort was 5.48 (P = 0.791). In the decision curve analysis of the training set, when the threshold probability was in the range of 5–63%, the net benefit of patients was greater than that of the two extreme curves. Preoperative malnutrition is an independent risk factor for EGAL. A diagnostic model, developed on age, anastomotic location, smoking status, and drinking history, was a reliable noninvasive tool to timely predict the occurrence of AL.
- 25 March 2025
- Published by Springer Nature in Perioperative Medicine
- Vol. 14 (1) , 1-12
Open AccessPrediction of esophagogastric anastomotic leakage by nomogram combined with preoperative nutritional status and clinical factors: a retrospective study of 775 patients
The purpose was to explore the independent risk factors for esophagogastric anastomotic leakage (EGAL) and establish a nomogram. Patients who underwent esophagectomy were enrolled and randomly divided into a training cohort and a validation cohort at a ratio of 7:3. The differences between the two groups of factors were analyzed by difference analysis, and multivariate regression analysis was subsequently performed. A nomogram was established, and the feasibility of the nomogram was verified by analyzing the discrimination, calibration, and decision curves. A total of 775 patients were enrolled, including 532 in the training cohort and 223 in the validation cohort. Multivariate regression analysis revealed that age, smoking history, drinking history, nutritional indicators, and anastomotic location were independent risk factors. In terms of discrimination, in the training group, the area under the curve was 0.757 (P = 0.025). In the calibration curve, the curves and fitting lines before and after correction in the training group and the validation group were basically the same. The results of the Hosmer–Lemeshow test showed that the chi-square value of the training cohort was 5.48 (P = 0.791). In the decision curve analysis of the training set, when the threshold probability was in the range of 5–63%, the net benefit of patients was greater than that of the two extreme curves. Preoperative malnutrition is an independent risk factor for EGAL. A diagnostic model, developed on age, anastomotic location, smoking status, and drinking history, was a reliable noninvasive tool to timely predict the occurrence of AL.